Reference
- Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169.
- Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New Engl J Med. 2004;351:1285–1295.
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New EnglJ Med. 2004;351:1296–1305.
- Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant. 1997;12:718–723.
- Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: An angiographic examination. J Am Soc Nephrol. 2005;16:1141–1148.
- Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–2567.
- Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007;50:1009–1019.
- Buiten MS, de Bie MK, Rotmans JI, et al. Serum cardiac troponin-i is superior to troponin-t as a marker for left ventricular dysfunction in clinically stable patients with end-stage renal disease. PLoS One. 2015;10:e0134245
- Hayashi T, Obi Y, Kimura T, et al. Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy. Nephrol Dial Transplant. 2008;23:2936–2942.
- Deegan PB, Lafferty ME, Blumsohn A, Henderson IS, McGregor E. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. Kidney Int.2001;60:2399–2405.
- Group NW, Wu AH, Jaffe AS, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: Use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53:2086–2096.
- Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992.
- Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. New Engl J Med. 2002;346:2047–2052.
- Guclu T, Bolat S, Senes M, Yucel D. Relationship between high sensitivity troponins and estimated glomerular filtration rate. Clin Biochem. 2016;49:467–471.
- Sittichanbuncha Y, Sricharoen P, Tangkulpanich P, Sawanyawisuth K. The appropriate troponin T level associated with coronary occlusions in chronic kidney disease patients. Ther Clin Risk Manag. 2015;11:1143–1147.
- Roberts MA, Hedley AJ, Ierino FL. Understanding cardiac biomarkers in end-stage kidney disease: Frequently asked questions and the promise of clinical application. Nephrology (Carlton). 2011;16:251–260.
- Ryu DR, Park JT, Chung JH, et al. A more appropriate cardiac troponin T level that can predict outcomes in end-stage renal disease patients with acute coronary syndrome. Yonsei Med J. 2011;52:595–602.
- Vafaie M, Biener M, Mueller M, et al. Addition of copeptin improves diagnostic performance of point-of-care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction – A pilot study. Int J Cardiol. 2015;198:26–30.